Abstracts tagged "COVID-19"

Abstract Number: 1760 • ACR Convergence 2022
Diagnoses Rates in Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients During COVID-19
W. Cliff Rutter, Will Cavers, Jean Park, Elisea Avalos-Reyes and Kjel Johnson, CVS Health, Lincoln, RI
Background/Purpose: COVID-19 is of particular concern to patients with autoimmune rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE).…
Abstract Number: 1932 • ACR Convergence 2022
Efficacy of the COVID-19 Vaccine in Pediatric Systemic Lupus Erythematosus Patients
Yi Shi¹, Catherine Park², Sangeeta Sule² and Sun-Young Ahn², ¹Children's National Hospital, New York, NY, ²Children's National Hospital, Washington, DC
Background/Purpose: The COVID-19 virus has caused significant morbidity and mortality, despite introduction of the COVID vaccine. Immunocompromised patients have been shown to have reduced response…
Abstract Number: 2214 • ACR Convergence 2022
Deep Immune Profiling Uncovers Novel Associations with Variable Clinical Phenotypes of Multisystem Inflammatory Syndrome in Children (MIS-C)
Christopher Redmond¹, Moses Kitakule², Riccardo Castagnoli³, Francesco Licciardi⁴, Cihan Oguz⁵, Maria Cecilia Poli⁶, Aran Son⁵, Sarah Weber⁵, Luigi Notarangelo⁷, Helen Su⁸ and Daniella Schwartz⁹, ¹National Institutes of Health, Rockville, MD, ²Columbia University, New York, NY, ³National Institute of Allergy and Infectious Diseases, Bethesda, MD, ⁴OSPEDALE REGINA MARGHERITA, Torino, Italy, ⁵National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ⁶Roberto del Rio, Santiago, Chile, ⁷NIAID/NIH, Bethesda, MD, ⁸NIH/NIAID, Bethesda, MD, ⁹National Institutes of Health Clinical Center, Bethesda, MD
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a systemic inflammatory condition that follows SARS-CoV2 infection or exposure in children. Clinical presentations are highly variable…
Abstract Number: 0188 • ACR Convergence 2022
COVID-19 and Autoimmune Rheumatic Patients: Behavioral Changes Adopted by Patients in the Midst of the Pandemic
Dzifa Dey¹, Bright Katso², Saudatu Issaka², Derrick Nyame³ and Patrick Adjei¹, ¹University of Ghana Medical School, Accra, Ghana, ²Rheumatology Unit Korle bu Teaching Hospital, Accra, Ghana, ³Korle bu Teaching Hospital, Accra, Ghana
Background/Purpose: Several changes following the COVID-19 pandemic have emerged globally regarding the delivery of healthcare services. Giving concerns that, patients with Autoimmune Rheumatic Disease (AIRD)…
Abstract Number: 0701 • ACR Convergence 2022
Reduced Humoral but Maintained Cellular Immune Response to a 3rd COVID-19 Vaccination in Patients with Immune-Mediated Inflammatory Diseases as Compared to Healthy Controls over a 3-months Observational Period
Daniel Mrak¹, Felix Kartnig¹, Daniela Sieghart¹, Elisabeth Simader¹, Helga Radner¹, Peter mandl², Lisa Göschl¹, Philipp Hofer³, Thomas Hummel¹, Thomas Deimel⁴, Irina Gessl⁴, Renate Kain⁵, Stefan Winkler⁶, Josef Smolen⁴, Thomas Perkmann⁷, Helmuth Haslacher⁷, Daniel Aletaha⁸, Leonhard Heinz¹ and Michael Bonelli¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria, ³Department of Pathology, Medical University of Vienna, Vienna, Austria, ⁴Medical University of Vienna, Vienna, Austria, ⁵Department of Pathology, Medical University of Vienna, Vienna, ⁶Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria, ⁷Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ⁸Medical University Vienna, Wien, Austria
Background/Purpose: A third COVID-19 vaccination is currently recommended for patients under immunosuppression. However, a fast decline of antibodies against the SARS-CoV-2 receptor-binding domain (RBD) of…
Abstract Number: 0765 • ACR Convergence 2022
The Impact of Immunomodulating Treatment on the Immunogenicity of COVID-19 Vaccines in Patients with Immune-mediated Inflammatory Rheumatic Diseases Compared to Healthy Controls. a Swedish Nationwide Study (COVID19-REUMA)
Martina Frodlund¹, Katerina Chatzidionysiou², Anna Södergren³, Eva Klingberg⁴, Anders A Bengtsson⁵, Monika Hansson², Sophie Ohlsson⁶, Elisa Pin⁷, Lars Klareskog⁸ and Meliha Kapetanovic⁹, ¹Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ²Department of Medicine, Solna, Division of Rheumatology, Karolinska University Hospital at Karolinska Institutet, Stockholm, Sweden, ³Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden and Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, Umeå, Sweden, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁵Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁶Department of Clinical Sciences, Lund, Section for Nephrology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁷Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Lund University, Department for clinical sciences Lund, section of rheumatology and Lund University Hospital Lund and Malmö, Lund, Sweden
Background/Purpose: The aim of the study was to elucidate antibody responses after vaccination with two doses of COVID-19 vaccines in patients with inflammatory rheumatic diseases…
Abstract Number: 0791 • ACR Convergence 2022
Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy
Ingrid Jyssum¹, Anne Therese Tveter¹, Joe Sexton¹, Ingrid Egeland Christensen¹, Siri Mjaaland², David Warren³, Tore K. kvien¹, Kristin Hammersbøen Bjørlykke⁴, Grete Birkeland Kro³, Jørgen Jahnsen⁴, Ludvig A. Munthe³, Espen Haavardsholm¹, Gunnveig Grødeland³, Sella Aarrestad Provan¹, Kristin Kaasen Jørgensen⁴, Guro Goll¹ and Silje Watterdal Syversen¹, ¹Diakonhjemmet Hospital, OSLO, Norway, ²Norwegian Institute of Public Health, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Akershus University Hospital, Oslo, Norway
Background/Purpose: Humoral vaccine responses to SARS-Cov-2 vaccines are impaired and short lasting in patients with immune-mediated inflammatory diseases (IMIDs). Concerns have been raised regarding their…
Abstract Number: 0913 • ACR Convergence 2022
Impact of Disease-modifying Antirheumatic Drugs on Immunogenicity to COVID-19 Vaccine in Patients with Rheumatoid Arthritis
Karam Jabri¹, Linda Burns² and Joseph Grisanti³, ¹University at Buffalo/Catholic Health, Depew, NY, ²Buffalo Rheumatology, Lancaster, NY, ³Buffalo Rheumatology & Medicine, Orchard Park, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of infection compared to healthy subjects (1). This is because of a multifactorial complex…
Abstract Number: 1293 • ACR Convergence 2022
Is Virtual Care Here to Stay? : Rheumatology Patients’ Satisfaction in Early vs Late Pandemic
Ummugulsum Gazel¹, Tommy Han², Seyyid Bilal Acikgoz³, Tara Swami¹, Hart goldhar⁴, Urusa Shah³, Rokshana Chowdhury³, Nataliya Milman³, Nancy Maltez¹, Catherine Ivory¹, Susan Humphrey-Murto³ and Sibel Aydin¹, ¹University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, ²University of Ottawa, Medical School, Ottawa, Canada, Ottawa, ON, Canada, ³University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, Canada, ⁴William Osler Health Centre Etobicoke General Site, Rheumatology, Toronto, ON, Canada
Background/Purpose: The COVID-19 pandemic has dramatically changed the delivery of healthcare, with virtual care becoming the new standard. In the early stages of the pandemic,…
Abstract Number: 1762 • ACR Convergence 2022
Stability of Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Other Autoimmune Biomarkers Among Clinical Patients Throughout the SARS-CoV-2 Pandemic and Vaccination Campaigns
Mark Rudolph, Rory Bloch, Anja Kammesheidt and Roberta Alexander, Exagen, Inc., Vista, CA
Background/Purpose: COVID-19 can cause autoantibody signatures in severely ill patients, and widespread emerging post-acute sequelae of SARS-CoV-2 (PASC) share many symptoms consistent with rheumatologic involvement…
Abstract Number: 1933 • ACR Convergence 2022
PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results
Gina Montealegre Sanchez¹, Roberta DeBiasi², Lauren Arrigoni², Kevin Rubenstein³, Jason Liang⁴, James Bost², Marcin Gierdalski², Max Wolff³, Mallory Barrix², Maureen Edu², Saira Huq², Shera Weyers³, Patricia Bandettini⁵, Dorothy Bulas², Tom Burklow⁶, Marcus Chen⁵, Sanchita Das⁶, Robin Dewar³, Joseph Fontana⁵, Ashraf Harahsheh², Linda Herbert², Anastassios Koumbourlis², Andrew Lipton⁵, Laura Olivieri², Dinesh Pillai², Vandana Sachdev⁵, Craig Sable², Audrey Thurm⁷, Evrim Turkbey⁶, Alexandra Yonts², Jonathan Zember², Eric Vilain², Meghan Delaney², Luigi Notarangelo⁴, David Wessel⁸ and Karyl Barron⁴, ¹NIAID/NIH, Garrett Park, MD, ²Children's National Hospital, Washington, DC, ³Frederick National Laboratory for Cancer Research, Frederick, MD, ⁴NIAID/NIH, Bethesda, MD, ⁵NHLBI/NIH, Bethesda, MD, ⁶CC/NIH, Bethesda, MD, ⁷NIMH/NIH, Bethesda, MD, ⁸Children's National Hospital, Washington, MD
Background/Purpose: The long-term complications of SARS-CoV-2 and MIS-C in children are unknown. PECOS, a joint study at the National Institutes of Health (NIH) Clinical Center…
Abstract Number: 2249 • ACR Convergence 2022
Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rheumatoid Arthritis: A Multicenter Comparative Study
Gabriel Figueroa Parra¹, Emily Gilbert², Maria Valenzuela Almada¹, Sebastian Vallejo¹, Matthew Neville³, Naomi Patel⁴, Claire Cook⁵, Xiaoqing Fu⁵, Ramla Hagi⁵, Gregory McDermott⁶, Michael Dilorio⁶, Lucy Masto⁶, Kathleen Vanni⁶, Emily Kowalski⁶, Grace Qian⁶, Zachary Wallace⁵, Ali Duarte-Garcia¹ and Jeffrey Sparks⁷, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Jacksonville, FL, ³Mayo Clinic, Phoenix, AZ, ⁴Massachusetts General Hospital, Sale Creek, TN, ⁵Massachusetts General Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) has been associated with severe COVID-19, but few studies have investigated outcomes in RA phenotypes such as interstitial lung disease (RA-ILD),…
Abstract Number: 0211 • ACR Convergence 2022
Determinants of COVID-19 Vaccine Hesitancy in a Predominantly Black Population with Cutaneous Lupus Erythematosus
Sophia Lutgen¹, S. Sam Lim², Laura D. Aspey², Gaobin Bao³, Charmayne Dunlop-Thomas², Jessica N. Williams² and Cristina Drenkard², ¹Mount Sinai Morningside-West, New York, NY, ²Emory University, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA
Background/Purpose: Due to demographic and disease-related factors, patients with lupus are deemed to be more vulnerable to COVID-19 infection than the general population, but they…
Abstract Number: 0702 • ACR Convergence 2022
Fourth SARS-CoV-2 Vaccine Dose in Rituximab Treated Patients: An Open Label Extension Study
Daniel Mrak¹, Elisabeth Simader¹, Daniela Sieghart¹, Peter mandl², Helga Radner¹, Thomas Perkmann³, Helmuth Haslacher³, Margareta Mayer⁴, Maximilian Koblischke⁴, Philipp Hofer⁵, Lisa Göschl¹, Felix Kartnig¹, Thomas Deimel⁶, Andreas Kerschbaumer⁶, Thomas Hummel¹, Barbara Kornek⁶, Renate Thalhammer³, Karin Stiasny⁴, Stefan Winkler⁷, Josef Smolen⁶, Judith Aberle⁴, Daniel Aletaha⁸, Leonhard Heinz¹ and Michael Bonelli¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria, ³Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ⁴Center for Virology, Medical University of Vienna, Vienna, Austria, ⁵Department of Pathology, Medical University of Vienna, Vienna, Austria, ⁶Medical University of Vienna, Vienna, Austria, ⁷Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria, ⁸Medical University Vienna, Wien, Austria
Background/Purpose: Humoral immune response to COVID-19 vaccination is vastly diminished in B-cell depleted patients, resulting in lower antibody titers in patients with a potential higher…
Abstract Number: 0769 • ACR Convergence 2022
Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial
Daniela Sieghart¹, Daniel Mrak¹, Elisabeth Simader¹, Selma Tobudic², Helga Radner¹, Peter Mandl³, Lisa Göschl¹, Maximilian Koblischke⁴, Nikolaus Hommer⁵, Lukas Hartl⁶, Philipp Hofer⁷, Felix Kartnig¹, Thomas Hummel¹, Andreas Kerschbaumer³, Thomas Deimel³, Antonia Puchner¹, Renate Thalhammer⁸, Andreas Zuckermann⁹, Karin Stiasny⁴, Thomas Perkmann⁸, Helmuth Haslacher⁸, Markus Zeitlinger⁵, Ursula Wiedermann¹⁰, Judith Aberle⁴, Daniel Aletaha¹¹, Leonhard Heinz¹ and Michael Bonelli¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴Center for Virology, Medical University of Vienna, Vienna, Austria, ⁵Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria, ⁶Division of Gastroenterology, Medical University of Vienna, Vienna, Austria, ⁷Department of Pathology, Medical University of Vienna, Vienna, Austria, ⁸Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ⁹Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, ¹⁰Institute of Specific Prophylaxis and Tropical Medicine, Center of Pathophysiology, Infectiology & Immunology, Medical University Vienna, Vienna, Austria, ¹¹Medical University Vienna, Wien, Austria
Background/Purpose: Patients under immunosuppressive therapy have a high risk for severe COVID-19 disease courses. However, efficacy of vaccination and therefore the right vaccination strategy remains…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].